Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.

Abstract

PURPOSE:

To evaluate the effect of posterior vitreomacular adhesion (VMA), documented by optical coherence tomography, on the outcome of anti-vascular endothelial growth factor treatment of polypoidal choroidal vasculopathy.

METHODS:

Medical records of 102 patients (104 eyes) with polypoidal choroidal vasculopathy were retrospectively reviewed and categorized according to the presence of posterior VMA into 2 subgroups: VMA positive (+) group (23 eyes) and VMA negative (-) group (81 eyes). Best-corrected visual acuity and central macular thickness after antivascular endothelial growth factor treatment were compared between the 2 groups at baseline and at 1 month, 3 months, 6 months, and 12 months.

RESULTS:

At the last follow-up, average number of injections was 4.82 ± 1.27 in the VMA (+) group and 4.92 ± 1.45 in the VMA (-) group. After injection, the mean logarithm of the minimum angle of resolution of best-corrected visual acuity improved from 0.81 ± 0.53 (Snellen equivalent, 20/129) to 0.67 ± 0.52 (Snellen equivalent, 20/93) in the VMA (+) group (P = 0.01) and from 0.79 ± 0.50 (Snellen equivalent, 20/123) to 0.64 ± 0.58 (Snellen equivalent, 20/91) in the VMA (-) group (P = 0.02). Average central macular thickness decreased from 354.4 ± 124.5 μm to 249.6 ± 112.5 μm in the VMA (+) group (P = 0.01) and from 361.2 ± 140.2 μm to 267.3 ± 103.5 μm in the VMA (-) group (P = 0.01). Polyp regression rate was 21.7% (5 eyes of 23 eyes) in the VMA (+) group and 22.2% (18 eyes of 81 eyes) in the VMA (-) group. There was no statistically significant difference in the best-corrected visual acuity improvement, central macular thickness improvement, and polyp regression rate between the groups.

CONCLUSION:

Unlike typical age-related macular degeneration, posterior VMA was not associated with a visual outcome after intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.

• Authors: Han Joo Cho, Ji Sun Baek, Dong Won Lee, Sung Won Cho, Chul Gu Kim, Jong Woo Kim
• Journal: Retina (Philadelphia, Pa.) (Retina) 2013 Nov-Dec Vol. 33 Issue 10 Pg. 2126-32 ISSN: 1539-2864 [Electronic] United States
• PMID: 23609123 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Coloring Agents
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab
• Indocyanine Green
• Ranibizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Choroid (blood supply)
• Choroid Diseases (drug therapy, physiopathology)
• Coloring Agents
• Female
• Fluorescein Angiography
• Humans
• Indocyanine Green
• Intravitreal Injections
• Macula Lutea (pathology)
• Male
• Middle Aged
• Polyps (drug therapy, physiopathology)
• Ranibizumab
• Retinal Diseases (pathology)
• Retrospective Studies
• Tissue Adhesions (pathology)
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)
• Vitreous Body (pathology)